Gene Expression Model Selector (GEMS) is a system that constructs, in a supervised fashion, diagnostic and outcome prediction models from array gene expression data. Examples of such models are: (a) models that detect cancer, (b) models that determine the correct subtype of cancer or (c) models that predict survival after treatment. Models that support such complex decision making are widely recognized as having the potential to revolutionize medicine in the years to come. In addition to the decision support models, GEMS can be used to select a small number of genes that are as good or better than the full gene set for diagnosis and/or outcome prediction. These biomarkers (genes) are also useful for discovery purposes (e.g., they suggest plausible causes and treatments of various types of cancer). Finally, GEMS provides estimates of the models' performance (e.g., accuracy) in future applications (i.e., when applied on patients not used to build the models but who come from the same patient population as the ones used to build the models), and allows users to run the models for individual patients.
This technology provides for a proteomic approach to grading gliomas, and for predicting patient survival. In addition to employing global protein expression patterns, such as by mass spectrometry, particular target proteins whose expression is altered in various gliomas can be used to predict the stage/classification of a glioma, as well as to indicate whether a given patient will be a short- or long-term survivor.
This technology provides for the simultaneous assessment of multiple tissue regions or microregions, the benefit being homogeneity of the sampling, both in terms of tissue content and timing. Discrete regions of a tissue sample, such as those demarcated by microwells formed within the tissue itself or tissue plugs removed from the tissue in a spatially referenced fashion, can be treated with one or more physical or chemical treatments to liberate target molecules of interest. Subsequent analysis of said target molecules by, e.g., mass spectroscopy, permits identification of a variety of biological parameters, including those associated with disease or therapy.
Dr. Liang has identified a new protein (termed "Killin") that represents a novel protein for cancer diagnosis, treatment and drug screening. Killin is a small (178 amino acids) nuclear DNA binding protein shown to play a role in cell cycle control.
Methods and apparatuses for analyzing proteins and other biological materials and xenobiotics within a sample. A specimen is generated, which may include an energy absorbent matrix. The specimen is struck with laser beams such that the specimen releases proteins. The atomic mass of the released proteins over a range of atomic masses is measured. An atomic mass window of interest within the range of atomic masses is analyzed to determine the spatial arrangement of specific proteins within the sample, and those specific proteins are identified as a function of the spatial arrangement. By analyzing the proteins, one may monitor and classify disease within a sample.Australia Patent 2002362961
The present invention is directed to particular human monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of respiratory syncytial virus infections. In particular, these antibodies may neutralize RSV. Also disclosed are improved methods for producing monoclonal antibodies.
Scientists at Vanderbilt have developed an entirely plasmid-based system to better utilize reoviruses as a research tool. The system allows for generating a reovirus entirely from cloned cDNAs comprising three steps involving fairly well-known techniques.
This invention provides bioluminescence resonance energy transfer (BRET) system that comprises four parts: 1) a bioluminescent protein that has luciferase activity; 2) an acceptor fluorophore that can accept the energy from the bioluminescent protein when they are associated, in the presence of the appropriate substrate; 3) a modulator that influences the proximity or the orientation of the bioluminescent protein and the fluorophore, and 4) an appropriate substrate to activate the luciferase activity of the bioluminescent protein. The components of this system interact to influence the spatial relationship between the bioluminescent protein and the fluorophore, that is demonstrated by the light emission from the system. The modulator can be a single entity, covalently attached to both the bioluminescent protein and the fluorophore, it can be two separate entities, each linked covalently to either the bioluminescent protein or the fluorophore, or an alternative configuration that falls within the scope of the invention. Thissystem can be used in both in vivo or in vitro assays to detect molecular changes in a wide variety of applications, and is amenable to automation. In particular, it is useful for assaying protein interactions, enzyme activities and the concentration of analytes or signaling molecules in cells or in solution.
A method of determining a local causal neighborhood of a target variable from a data set can include identifying variables of the data set as candidates of the local causal neighborhood using statistical characteristics, and including the identified variables within a candidate set. False positive variables can be removed from the candidate set according to further statistical characteristics applied to each variable of the candidate set. The remaining variables of the candidate set can be identified as the local causal neighborhood of the target variable.
Vanderbilt researchers have discovered specific morphogens that can promote differentiation of embryonic stem cells to cardiomyocytes. In addition when these morphogens are added to stem cells during differentiation a 10 to 20 fold increase is seen in cardiomyocyte formation. Thus addition of such morphogens may prove to be a valid therapy for cardiac repair and regeneration.
Vanderbilt researchers have identified compounds that selectively differentiate stem cells into cardiomyocytes by perturbing key pathways. Medicinal chemistry is currently underway to develop lead compounds that maybe used for the treatment of damaged cardiac muscle.
This is a genetically engineered mouse ES stem cell line marking cardiomyocytes with red fluorescent protein (RFP). These cells have been used in high-throughput screens by Vanderbilt researchers for pro-cardiogenic factors. In addition the construct used in this cell line could be used to mark the cardiac progeny of transplanted stem cells, generate stable human ES cell lines, or engineer iPS for cardiac lineage studies.
Dr. Piston's group has generated a variant of the enhanced cyan fluorescent protein (ECFP) that has improved brightness, more resistance to photo-bleaching and a fluorescence lifetime that is best fit by a single exponential.